Global health – France will host the Global Forum for Vaccine Sovereignty and Innovation in Paris on June 20 (25 April 2024)
During World Immunization Week, France is announcing that it will co-host the Global Forum for Vaccine Sovereignty and Innovation with the African Union (AU) and Gavi, the Vaccine Alliance. This event will be held in Paris on June 20.
This Forum has two objectives:
- It will launch the African Vaccine Manufacturing Accelerator (AVMA). Based on the lessons learned from the Covid pandemic, this innovative mechanism is an important step toward African sovereignty in the field of health. AVMA will provide funding for regional vaccine manufacturing on the African continent. Conceived by Gavi in close consultation with African disease prevention and control centers, it will contribute to the AU’s goal of manufacturing at least 60% of the vaccine doses needed by Africa on the African continent by 2040.
- It will also mark the start of Gavi’s replenishment campaign for 2026-2030. The Vaccine Alliance makes significant progress possible in the fight against such infectious diseases as malaria, dengue and cholera, whose risks of spreading are increased by climate disruption. It also contributes to better prevention of cervical cancer in women and girls.
These two objectives, which are cornerstones of France’s global health strategy, are at the heart of the 2030 Agenda. The Global Forum for Vaccine Sovereignty and Innovation in Paris co-organized with the AU and Gavi will reflect that commitment.
France and its European partners are strongly committed to boosting immunization efforts worldwide and to supporting fair access to vaccines for all. To help its partners deal with the Covid-19 pandemic, France made more than 126 million vaccine doses available, especially to African countries, as part of the Access to Covid-19 Tools Accelerator (ACT-A). France was one of the principal initiators of this collaboration.
Learn more about France’s role in Gavi, the Vaccine Alliance
France is the sixth-largest donor to Gavi, and has allocated some €800 million to the Alliance and to COVAX, ACT-A’s vaccine component, for the period of 2021-2025. Gavi, the Vaccine Alliance, is a public-private partnership that has helped vaccinate more than half of the world’s children against some of the deadliest diseases. Since its establishment in 2000, Gavi has helped vaccinate an entire generation – more than a billion children – and to prevent some 17.3 million deaths in the long term, reducing childhood mortality in 78 low-income countries by half.